Clinical trials: Renal Tumors
Metastatic Renal Cell Carcinoma (mRCC)
International Multicentric Study ARON-1
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.
- Trial name
- NCT05287464
- Testing
- pembrolizumab plus axitinib
- Where
- Italy
- Volunteers
- 1,220 people
- Sponsor
- Hospital of Macerata
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Renal Tumor
Cost-effectivness of Robot-assisted Surgery Compared to Open Surgery for Partial Nephrectomy in Context of Renal Tumor
This study aim to analyze cost-effectiveness of robot-assisted surgery compared to open surgery for partial nephrectomy in the context of renal tumor.
- Trial name
- écoREIN (NCT05089006)
- Testing
- Partial nephrectomy with robot-assisted and open surgery
- Volunteers
- 400 people
- Sponsor
- Central Hospital, Nancy, France
Advanced Malignancies, Metastatic Cancer
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT02923349
- Testing
- INCAGN01949
- Where
- 8 sites in United States, Spain and 2 more
- Volunteers
- 87 people
- Sponsor
- Incyte Biosciences International Sàrl
Kidney Cancer
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00401128
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Metastatic Clear Cell Renal Cell Carcinoma
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with advanced clear cell renal cell carcinoma using RECIST criteria.
- Trial name
- NCT02002312
- Testing
- Lu-177-DOTA-girentuximab
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Kidney Cancer
A Prospective Post-Market Study to Evaluate the Clinical Utility of IRIS, a Three-dimensional (3-D) Anatomical Modeling Software for Pre-operative Surgical Planning and Intra-operative Navigation for Nephrectomy
This is a prospective, multi-center, post-market study to evaluate the clinical utility of IRIS, a 3D anatomical modeling software, with standard CT scans during pre-operative planning and intra-operative navigation for…
- Trial name
- NCT04329767
- Testing
- IRIS 1.0
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- Intuitive Surgical
Myoma
Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy
In this study, the investigators will investigate the effectiveness of a topical tranexamic acid plus perivascular vasopressin compared with perivascular vasopressin alone for the reduction of blood loss at the time of myomectomy
- Trial name
- NCT03880045
- Testing
- Topical TA, vasopressin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Aswan University Hospital
Carcinoma, Renal Cell
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer.
- Trial name
- NCT00502307
- Testing
- Tivozanib (AV-951)
- Where
- 26 sites in India, Russia and 1 more
- Volunteers
- 272 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Kidney Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
RATIONALE: Warm ischemia is the clamping of blood vessels without cooling the kidney. Cold ischemia is the clamping of blood vessels with kidney cooling.
- Conditions
- Kidney Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Perioperative/Postoperative Complications, Urinary Complications
- Trial name
- NCT00743236
- Testing
- cold ischemia procedure, warm ischemia procedure
- Where
- 8 sites in United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments.
- Conditions
- Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract
- Trial name
- NCT06161532
- Testing
- Sacituzumab govitecan, Atezolizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003584
- Testing
- estramustine phosphate sodium, prednisone, vinorelbine tartrate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of New Mexico
Carcinoma, Renal Cell, Glioblastoma
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually…
- Conditions
- Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
- Trial name
- NCT01441388
- Testing
- Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
The purpose of this study is to test the safety of an investigational vaccine called TroVax when given in conjunction with Interleukin-2 (IL-2) treatment.
- Trial name
- NCT00083941
- Testing
- TroVax, Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oxford BioMedica
Chronic Kidney Disease, Stage 3 (Moderate)
Short-term Effect of a New Nordic Renal Diet on Phosphorus Homeostasis in CKD Stage 3-4
Hyperphosphatemia is a severe complication to chronic kidney disease (CKD) and is associated with increased risk of vascular calcification, cardiovascular morbidity and mortality.
- Trial name
- NCT03472105
- Testing
- New Nordic Renal Diet
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- University of Copenhagen
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Renal Cell Carcinoma, Melanoma
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4…
- Conditions
- Renal Cell Carcinoma, Melanoma, Lung Cancer
- Trial name
- NCT02763761
- Testing
- Infliximab + Prednisone, Methylprednisolone + Prednisone
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb
Clear Cell Renal Carcinoma
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
The therapeutic scenario of metastatic renal cancer is undergoing a new revolution with the appearance of a novel therapeutic strategy after the antiangiogenic treatments, that is the immunotherapy, in addition to the approval of…
- Trial name
- INMUNOSUN (NCT03066427)
- Testing
- Sunitinib
- Where
- 9 sites in Spain
- Volunteers
- 23 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Collecting Duct Carcinoma (Kidney)
Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
Open-label, non-randomized, multicenter, phase II, single arm non comparative trial evaluating toxicity and efficacy of gemcitabine plus platinum salt in combination with bevacizumab in first-line setting in metastatic collecting…
- Trial name
- BEVABEL (NCT02363751)
- Testing
- Bevacizumab
- Where
- 19 sites in France
- Volunteers
- 36 people
- Sponsor
- UNICANCER
Cancer, Cisplatin Adverse Reaction
Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury
Cisplatin is a potent chemotherapeutic agent, however, its nephrotoxicity manifested by acute kidney injury (AKI) often limits applicability.
- Trial name
- NCT02250872
- Testing
- Gemigliptin, Cisplatin
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Seoul National University Bundang Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.